{"id":"candemore-tablet","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"5-8","effect":"Headache"},{"rate":"3-5","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug binds to angiotensin II type 1 (AT1) receptors on vascular smooth muscle and other tissues, preventing angiotensin II-mediated vasoconstriction and aldosterone release. This leads to vasodilation, reduced peripheral vascular resistance, and decreased blood pressure. ARBs like candesartan (the active ingredient) are commonly used as first-line agents for hypertension management.","oneSentence":"Candemore is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce vasoconstriction and lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:15.002Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Essential hypertension"},{"name":"Heart failure with reduced ejection fraction"}]},"trialDetails":[{"nctId":"NCT04521023","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-09-20","conditions":"Hypertension","enrollment":132},{"nctId":"NCT01682564","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-01","conditions":"Hypertension, Congestive Heart Failure","enrollment":169},{"nctId":"NCT01766505","phase":"PHASE4","title":"The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)","status":"TERMINATED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-06","conditions":"Hypertension","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35895,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Candemore tablet","genericName":"Candemore tablet","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candemore is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce vasoconstriction and lower blood pressure. Used for Essential hypertension, Heart failure with reduced ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}